A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials
Key Points
Key points are not available for this paper at this time.
Abstract
Not available.
اسأل الذكاء الاصطناعي
Like
Bookmark
Share
View Full Paper
اسأل الذكاء الاصطناعي
Like
Bookmark
Share
View Full Paper
A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials | Synapse